| Ytd | 29.43% | |
| 1y | 72.63% |
| Open | 27.30 | Prev Close | 27.21 | Low | 26.38 | High | 27.59 | Mkt Cap | 527.83M |
| Vol | 330.59K | Avg Vol | 205.06K | EPS | -4.57 | P/E | N/A | Forward P/E | -10.16 |
| Beta | 3.31 | Short Ratio | 3.54 | Inst. Own | 46.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 32.09 | 200-d Avg | 27.73 | 1yr Est | 74.67 |
TECX News
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tec
Tectonic Therapeutic offers a validated, severity-enriched trial design for TX45 in CpcPH-HFpEF, wit
Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight an
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the ana
Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension ass
APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary
Raymond James analyst Michael Freeman upgrades Tectonic Therapeutic (NASDAQ:TECX) from Outperform
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.34) per share which missed the a
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tecto
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tec
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension
Stifel analyst James Condulis initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Buy
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received a consensus rati
Aberdeen Group plc boosted its holdings in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 22
Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by
Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus rating of "Mo
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.03) per share which beat the ana
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tect
Tiziana Life Sciences (NASDAQ: TLSA - Get Free Report) and Tectonic Therapeutic (NASDAQ: TECX - Get
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received an average ratin
Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pul
Tectonic Therapeutic, Inc. ( TECX ) Discusses Positive Topline Results From Phase Ib Part B Trial of
